Skip to main content

Table 1 Average plasma total and LDL cholesterol concentrations during follow-up

From: The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]

Baseline characteristic Plasma total cholesterol (mmol/l) Plasma LDL cholesterol (mmol/l)
  Simvastatin Placebo Difference* Simvastatin Placebo Difference*
Sex       
Male 4.1 5.3 -1.2 2.2 3.2 -1.0
Female 4.6 5.8 -1.2 2.5 3.4 -0.9
Age (years)       
<65 4.3 5.4 -1.1 2.4 3.2 -0.9
≥65 <70 4.1 5.4 -1.3 2.2 3.3 -1.0
≥70 4.2 5.5 -1.3 2.2 3.3 -1.1
Total cholesterol (mmol/L)       
<5.0 3.5 4.6 -1.1 1.8 2.6 -0.9
≥5.0 <6.0 4.0 5.2 -1.2 2.1 3.1 -1.0
≥6.0 4.8 6.0 -1.2 2.7 3.7 -1.0
LDL cholesterol (mmol/L)       
<3.0 3.7 4.9 -1.1 1.8 2.7 -0.9
≥3.0 <3.5 4.1 5.3 -1.2 2.2 3.2 -1.0
≥3.5 4.7 5.9 -1.2 2.7 3.7 -1.0
ALL PATIENTS 4.2 5.4 -1.2 2.3 3.3 -1.0
  1. * Intention-to-treat comparisons with missing data imputed from initial pre-treatment screening values. The absolute difference in LDL-cholesterol that would be produced by full compliance with 40 mg simvastatin daily can be estimated as the ratio of the absolute difference to the estimated compliance. For example, -1.0/67% = -1.5 mmol/L.